Vnitr Lek 2007, 53(7-8):877-908

Doporučení pro diagnostiku a léčbu chronického srdečního selhání ČKS 2006

J. ©pinar1,*, J. Hradec2, J. Meluzín3, J. ©pác4, L. ©pinarová3, J. Vítovec3, P. Lupínek5, I. Málek5
1 Interní kardiologická klinika Lékařské fakulty MU a FN Brno, pracoviątě Bohunice, přednosta prof. MUDr. Jindřich ©pinar, CSc., FESC
2 III. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. ©těpán Svačina, DrSc., MBA
3 I. interní kardioangiologická klinika Lékařské fakulty MU a FN u sv. Anny, Brno, přednosta prof. MUDr. Jiří Vítovec, CSc., FESC
4 II. interní klinika Lékařské fakulty MU a FN u sv. Anny, Brno, přednosta doc. MUDr. Miroslav Souček, CSc.
5 Klinika kardiologie IKEM Praha, přednosta prof. MUDr. Josef Kautzner, CSc., FESC

Received: February 8, 2007; Published: July 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©pinar J, Hradec J, Meluzín J, ©pác J, ©pinarová L, Vítovec J, et al.. Doporučení pro diagnostiku a léčbu chronického srdečního selhání ČKS 2006. Vnitr Lek. 2007;53(7-8):877-908.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6 500 patients in randomised trials. Lancet 1997; 350: 1417-1424.
    2. Anand IS, Florea VG Diuretics in chronic heart failure - benefits and hazards. Eur Heart J 2001; 3 (Suppl G): G8-G18. Go to original source...
    3. Aschermann M et al. Kardiologie. Praha: Galen, 2004: 1481.
    4. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375-380. Go to original source...
    5. Baker DW, Jones R, Hogdes J et al. Management of heart failure, III: the role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction. JAMA 1994; 272: 1528-1534. Go to original source... Go to PubMed...
    6. Baker DW Prevention of heart failure. J Card Fail 2002; 8: 333-346. Go to original source... Go to PubMed...
    7. Bakris GL, Weir MR Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160: 685-693. Go to original source... Go to PubMed...
    8. Bardy GH, Lee KL, Mark DB et al. for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. New Engl J Med 2005; 352: 225-237. Go to original source... Go to PubMed...
    9. Bart BA, Boyle A, Bank AJ et al. Ultrafiltration Versus Usual Care for Hospitalized Patients With Heart Failure. J Am Coll Cardiol 2005; 46: 2043-2046. Go to original source... Go to PubMed...
    10. Bax JJ, Abraham T, Barold SS et al. Cardiac resynchronization therapy, I: issues before device implantation. J Am Coll Cardiol 2005; 46: 2153-2167. Go to original source... Go to PubMed...
    11. Bax JJ, Abraham T, Barold SS et al. Cardiac resynchronization therapy, II: issues during and after device implantation and unresolved questions. J Am Coll Cardiol 2005; 46: 2168-2182. Go to original source... Go to PubMed...
    12. Bax JJ, Bleeker GB, Marwick TH et al. Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy. J Am Coll Cardiol 2004; 44: 1834-1840. Go to original source... Go to PubMed...
    13. Berry C, McMurray JJ Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart 2001; 85: E8. Go to original source... Go to PubMed...
    14. Boehmer JP CRT only or CRT plus ICD? Eur Heart J 2004; 6 (Suppl): D83-D87. Go to original source...
    15. Bradley DJ, Bradley EA, Baughman KL et al. Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA 2003; 289: 730-740. Go to original source... Go to PubMed...
    16. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New Engl J Med 2001; 345: 861-869. Go to original source... Go to PubMed...
    17. Bristow MR, Saxon LA, Boehmer J et al. for COMPANION Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. New Engl J Med 2004; 350: 2140-2150. Go to original source... Go to PubMed...
    18. Byteąník J Doporučené postupy pro diagnostiku a léčbu komorových arytmií. Cor Vasa 2005; 47: Suppl: 41-57.
    19. CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13. Go to original source...
    20. Cleland JG, Daubert JC, Erdmann E et al. Cardiac Resynchronization-Heart Failure (CARE-HF) Study Group. The effect of cardiac resynchronization on morbidity and mortality in heart failure. New Engl J Med 2005; 352: 1539-1549. Go to original source... Go to PubMed...
    21. Cífková R, Býma S, Čeąka R et al. Prevence kardiovaskulárních onemocnění v dospělém věku. Společné doporučení českých odborných společností. Cor Vasa 2005; 47: Suppl: 3-14. Go to PubMed...
    22. Cleland JG, Swedberg K, Follath F et al. The Euro Heart Failure Survey Programme - survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003; 24: 442-463. Go to original source... Go to PubMed...
    23. Cleland JGF, Findlay I, Jafri S et al. The Warfarin/Aspirin Study in Heart Failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004; 148: 157-164. Go to original source... Go to PubMed...
    24. Cleland JGF, Tendera M et al. Perindopril in Elderly People with Chronic Heart Failure (PEP CHF): v tisku.
    25. Cockcroft DW, Gault MH Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41. Go to original source... Go to PubMed...
    26. Cokkinos DV, Harabalopoulos GC, Kostis JB et al. for the HELLAS investigators. Efficacy of antithrombotic therapy in chronic heart failure. Eur J Heart Fail 2006; 8: 428-432. Go to original source... Go to PubMed...
    27. Čihák R, Heinz P Doporučení pro léčbu fibrilace síní. Cor Vasa 2004; 46: K46-K78.
    28. de Silva R, Nikitin NP, Witte KKA et al. Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. Eur Heart J 2006; 27: 569-581. Go to original source... Go to PubMed...
    29. Deng MC, Edwards LB, Hertz MI et al. Mechanical circulatory support device database of the International Society for Heart and Lung Transplantation: third annual report, 2005. J Heart Lung Transplant 2005; 24: 1182-1187. Go to original source... Go to PubMed...
    30. Dormans TP, Huige RM, Gerlag PG Chronic intermittent haemofiltration and haemodialysis in end stage chronic heart failure with oedema refractory to high dose frusemide. Heart 1996; 75: 349-351. Go to original source... Go to PubMed...
    31. Dries DL, Exner DV, Domanski MJ et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35: 681-689. Go to original source... Go to PubMed...
    32. Dries DL, Exner DV, Gersh DC et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials: Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998; 32: 695-703. Go to original source... Go to PubMed...
    33. European Study Group on Diastolic Heart Failure. How to diagnose diastolic heart failure. Eur Heart J 1998; 19: 990-1003. Go to original source... Go to PubMed...
    34. Fabbri LM, Hurd SS Global strategy for the diagnosis, management and prevention of COPD: 2003 update. Eur Respir J 2003; 22: 1-2. Go to original source... Go to PubMed...
    35. Feldman AM, de Lissovoy G, Bristow MR et al. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol 2005; 46: 2311-2321. Go to original source... Go to PubMed...
    36. Flather MD, Shibata MC, Coats AJ et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215-225. Go to original source... Go to PubMed...
    37. Fuster V, Smith SC, Jakobs DT et al. ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines and policy conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of pacing and electrophysiology. Circulation 2001; 104: 2118-2150. Go to original source...
    38. Garcia MJ, Thomas JD, Klein AL New doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol 1998; 32: 865-875. Go to original source... Go to PubMed...
    39. Gheorghiade M, Gattis WA, O'Connor ChM Effects of Tolvaptan a Vassopresin Antagonist, in Patients Hospitalized With Worsening Heart Failure. Randomized Controlled Trial. JAMA 2004; 291: 1963-1971. Go to original source... Go to PubMed...
    40. Gibbs ChR, Blann AD, Watson RDS et al. Abnormalities of Hemorheological, Endothelial, and Platelet Function in Patients With Chronic Heart Failure in Sinus Rhythm. Circulation 2001; 103: 1746-1751. Go to original source... Go to PubMed...
    41. Goodlin SJ, Hauptman PJ, Arnold R et al. Consensus Statement: Palliative and Supportive Care in Advanced Heart Failure. J Card Fail 2004;10:200-9. Go to original source... Go to PubMed...
    42. Grimm W, Christ M, Bach J, et al. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy study. Circulation 2003; 108: 2883-2891. Go to original source... Go to PubMed...
    43. Haller Ch Diuretics in congestive heart failure: new evidence for old problems. Nephrol Dial Transplant 1999; 14: 1358-1360.
    44. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259. Go to original source...
    45. Hershberger RE, Nauman D, Walker TL et al. Care Processes and Clinical Outcomes of Continuous Outpatient Support with Inotropes (COSI) in Patients with Refractory Endstage Heart Failure. J Card Fail 2003; 9: 180-187. Go to original source... Go to PubMed...
    46. Hess B Chronic heart failure: pathophysiology and therapeuttic approaches - why is the kidney so important? Eur Heart J 2001; 3 (Suppl G): G3-G7. Go to original source...
    47. Hillege HL, Girbes AR, de Kam PJ et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102: 203-210. Go to original source... Go to PubMed...
    48. Hillege HL, Nitsch D, Pfeffer M et al. Renal function as a Predictor of Outcome in a Broad Spectrum of Patients with Heart Failure. Circulation 2006; 113: 671-678. Go to original source... Go to PubMed...
    49. Hradec J Srdeční selhání - epidemie 21. století. Vnitř Lék 2004; 50 (Suppl. 1): S23-S31.
    50. Hradec J Srdce a endokrinní onemocnění. In: Aschermann M, Widimský P, Veselka J (eds.): Kardiologie. 2. díl. Praha: Galén, 2004: 1369-1382.
    51. Hradec J Klinická studie CORONA. Je podávání statinů indikováno i u nemocných se symptomatickým systolickým srdečním selháním? Remedia 2005; 15: 169-171.
    52. Hradec J Diastolické srdeční selhání. In: Habilitační a inaugurační přednáąky na 1. lékařské fakultě UK v Praze 2004. Praha: Galén, 2005: 148-154.
    53. Hradec J, Berka L, Táborský M Posuzování způsobilosti kardiologických nemocných k řízení motorových vozidel (Dokument ČKS). Cor Vasa 2006; 48: K47-K51.
    54. Hradec J Farmakoterapie v kardiologii. In: Marek J et al. Farmakoterapie vnitřních nemocí. 3. vydání. Praha: Grada Publishing, 2005: 25-62.
    55. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 guidelines update for the diagnosis and management of chronic heart failure in the adult: summary article: a report from the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evolution and Management of Heart Failure). Circulation 2005; 112: 1825-1852. Go to original source...
    56. Jansa P, Aschemann M, Riedel M et al. Doporučení pro diagnostiku a léčbu arteriální plicní hypertenze. Cor Vasa 2004; 46: K35-K44.
    57. Kettner J Mechanické podpory krevního oběhu. Cor Vasa 2003; 45: 437-443.
    58. Kjekshus J, Dunselman P, Blideskog M et al. on behalf of the CORONA Study Group: A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics. Eur J Heart Fail 2005; 7: 1059-1069. Go to original source... Go to PubMed...
    59. Kloner RA, Brown M, Prisant LM et al. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Am J Hypertens 2001; 14: 70-73. Go to original source... Go to PubMed...
    60. Knight EL, Glynn RJ, McIntyre KM et al. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). Am Heart J 1999; 138: 849-855. Go to original source... Go to PubMed...
    61. Kohama A, Tanouchi J, Hori M et al. Pathologic involvement of the left ventricle in chronic cor pulmonale. Chest 1990; 98: 794-800. Go to original source... Go to PubMed...
    62. Kostis JB, Davis BR, Cutler J et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1997; 278: 212-216. Go to original source...
    63. Lachmanová J Očiątovací metody krve. Praha: Grada Publishing, 1999: 132.
    64. Lewis EF, Johnson PA, Johnson W et al. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant 2001; 20: 1016-1024. Go to original source... Go to PubMed...
    65. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. Published erratum appears in New Engl J Med 1993; 330: 152. New Engl J Med 1993; 329: 1456-1462. Go to original source... Go to PubMed...
    66. Linde C Implantable cardioverter-defibrillator treatment and resynchronisation in heart failure. Heart 2004; 90: 231-234.
    67. Ljungman S, Kjekshus J, Swedberg K Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol 1992; 70: 479-487. Go to original source... Go to PubMed...
    68. Ljungman S, Laragh JH, Cody RJ Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. Drugs 1990; 39 Suppl 4: 10-21. Go to original source... Go to PubMed...
    69. Loh E, Sutton MS, Wun CC et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. New Engl J Med 1997; 336: 251-257. Go to original source... Go to PubMed...
    70. López-Sendón J, Swedberg K, McMurray J et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004; 25: 1341-1362. Go to original source... Go to PubMed...
    71. Lucas C, Johnson W, Hamilton MA et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J 2000; 140: 840-847. Go to original source... Go to PubMed...
    72. Lukl J, Heinc P et al. Moderní léčba arytmií. Praha: Grada Publishing, 2001: 173-177.
    73. Lupínek P Význam a léčba anemie u chronického srdečního selhání. Cor Vasa 2004; 46: 281-284.
    74. Maisel AS, Krishnaswamy P, Nowak RM et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. New Engl J Med 2002; 347: 161-167. Go to original source... Go to PubMed...
    75. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
    76. Málek F, Ignaszewski A Nové léky pro terapii pokročilého srdečního selhání. Cor Vasa 2004; 46: 221-225.
    77. Mancini DM, Eisen H, Kussmaul W et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991; 83: 778-786. Go to original source... Go to PubMed...
    78. Masoudi FA, Wolfe P, Havranek EP et al. Aspirin use in older patients with heart failure and coronary artery disease: national prescription patterns and relationship with outcomes. J Am Coll Cardiol 2005; 46: 955-962. Go to original source...
    79. Massie BM, Krol WF, Ammon SE et al. The warfarin and antiplatelet therapy in heart failure trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail 2004; 10: 101-112. Go to original source... Go to PubMed...
    80. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353: 2001-2007. Go to original source...
    81. Morgan JM The MADIT II and COMPANION studies: will they affect uptake of device treatment? Heart 2004; 90: 243-245. Go to original source... Go to PubMed...
    82. Moss AJ, Zareba W, Hall WJ et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. New Engl J Med 2002; 346: 877-883. Go to original source... Go to PubMed...
    83. Moss AJ MADIT-II and its implications. Eur Heart J 2003; 24: 16-18. Go to original source... Go to PubMed...
    84. Mosterd A, Hoes AW, de Bruyne MC et al. Prevalence of heart failure and left ventricular dysfunction in the general population. Eur Heart J 1999; 20: 447-455. Go to original source... Go to PubMed...
    85. Murdoch DR, Love MP, Robb SD et al. Importance of heart failure as a cause of death. Changing contribution to overall mortality and coronary heart disease mortality in Scotland 1979-92. Eur Heart J 1998; 19: 1829-1835. Go to original source... Go to PubMed...
    86. Nagueh SF, Middleton KJ, Kopelen HA et al. Doppler tissue imaging: A noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997; 30: 1527-1533. Go to original source... Go to PubMed...
    87. Okada RD, Hager WD, Graves PE et al. Relationship between plasma concentration and dose of digoxin in patients with and without renal impairment. Circulation 1978; 58: 1196-1203. Go to original source... Go to PubMed...
    88. Ommen SR, Nishimura RA, Appleton CP et al. Clinical utility of doppler echocardiography and tissue doppler imaging in the estimation of left ventricular filling pressures. Circulation 2000; 102: 1788-1794. Go to original source... Go to PubMed...
    89. Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. New Engl J Med 2001; 344: 1651-1658. Go to original source... Go to PubMed...
    90. Packer M, Poole-Wilson PA, Armstrong PW et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100: 2312-2318. Go to original source... Go to PubMed...
    91. Pauwels RA, Buist AS, Ma P et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care 2001; 46: 798-825.
    92. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New Engl J Med 2003; 348: 1309-1321. Go to original source... Go to PubMed...
    93. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New Engl J Med 1999; 341: 709-717. Go to original source... Go to PubMed...
    94. Poole-Wilson PA, Swedberg K, Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362: 7-13. Go to original source... Go to PubMed...
    95. Priori SG, Aliot E, Blomstrom-Lundqvist C et al. Task force on sudden cardiac death of the European Society of Cardiology. Eur Heart J 2001; 22: 1374-1350. Go to original source... Go to PubMed...
    96. Rambausek M, Ritz E Digitalis in chronic renal insufficiency. Blood Purif 1985; 3: 4-14. Go to original source... Go to PubMed...
    97. Rathore SS, Wang Y, Krumholz HM Sex-based differences in the effect of digoxin for the treatment of heart failure. New Engl J Med 2002; 347: 1403-1411. Go to original source... Go to PubMed...
    98. Rathore SS, Curtis JP, Wang Y et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289: 871-878. Go to original source... Go to PubMed...
    99. Remes J, Miettinen H, Reunanen A et al. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 1991; 12: 315-321. Go to original source... Go to PubMed...
    100. Remme WJ Should ACE inhibitors Always be First - Line Therapy in Heart Fauilure? Lessons from the CARMEN Study. Cardiovasc Drugs Ther 2003; 17: 107-109. Go to original source... Go to PubMed...
    101. Render ML, Weinstein AS, Blaustein AS Left ventricular dysfunction in deteriorating patients with chronic obstructive pulmonary disease. Chest 1995; 107: 162-168. Go to original source... Go to PubMed...
    102. Reyes AJ, Taylor SH Diuretics in Cardiovascular Therapy: The new Clinicopharmacological Bases That Matter. Cardiovasc Drug Ther 1999; 13: 371-398. Go to original source...
    103. Rimondini A, Cipolla CM, Della Bella P et al. Hemofiltration as short-term treatment for refractory congestive heart failure. Am J Med 1987; 83: 43-48. Go to original source... Go to PubMed...
    104. Rosolova H, Cech J, Simon J et al. Short to long term mortality of patients hospitalized in the Czech republic - report from the EuroHeart Failure Survey. Eur J Heart Fail 2005; 7: 780-783. Go to original source... Go to PubMed...
    105. Salpeter SR, Greyber E, Pasternak GA et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Arch Intern Med 2003; 163: 2594-2602. Go to original source...
    106. Shlipak MG Pharmacotherapy for Heart Failure in Patients with Renal Insuficiency. Ann Int Med 2003; 138: 917-924.
    107. Sohn DW, Chai IH, Lee DJ et al. Assessment of mitral annulus velocity by doppler tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol 1997; 30: 474-480. Go to original source... Go to PubMed...
    108. Staessen JA, Wang JG, Thijs L Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358: 1305-1315. Go to original source... Go to PubMed...
    109. Stevenson LW. The Cul-de-Sac at the End of the Road. J Card Fail 2003; 188-91. Go to original source... Go to PubMed...
    110. Swedberg K, Cleland J, Dargie H et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115-1140. Go to original source... Go to PubMed...
    111. ©pinar J, Hradec J, Málek I et al. Doporučení pro diagnostiku a léčbu chronického srdečního selhání. Cor Vasa 2001; 43: K123-K138.
    112. ©pinar J, Janský P, Kettner J et al. Doporučení pro diagnostiku a léčbu akutního srdečního selhání. Cor et Vasa 2006; 48: K3-K31.
    113. ©pinar J, Ludka O, Duąek L et al. Neurohumoral activity, heart failure and prognosis in patients with end stage renal disease treated by chronic hemodialysis. In press.
    114. ©pinar J, Vítovec J Betablokátory a závaľné chronické srdeční selhání. Cor Vasa 2000; 42: 491-492.
    115. ©pinar J, Vítovec J Normy pro BNP a NT-proBNP stanoveny. Cor Vasa 2005; 47: 395-398.
    116. ©pinar J, Vítovec J Co by měl vědět internista o diastolickém srdečním selhání. Interní medicína pro praxi 2005; 7: 527-533.
    117. Táborský M Zásady pro implantace kardiostimulátorů a implantabilních kardioverterů-defibrilátorů pracovní skupiny pro arytmie a kardiostimulaci České kardiologické společnosti. Cor Vasa 2001; 43: K32-K41.
    118. The Capricorn Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357: 1385-1390. Go to original source... Go to PubMed...
    119. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New Engl J Med 1987; 316: 1429-1435. Go to original source... Go to PubMed...
    120. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. New Engl J Med 1997; 336: 525-533. Go to original source... Go to PubMed...
    121. The EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.
    122. The Stroke Prevention in Atrial Fibrilation Investigators. Predictors in thromboembolism in atrial fibrillation. Clinical features of patients at risk. Ann Intern Medicine 1992; 116: 1-5. Go to original source... Go to PubMed...
    123. Vítovec J, ©pinar J Betablokátory v léčbě chronického srdečního selhání. Vnitř Lék 2000; 46: 161-165. Go to PubMed...
    124. Vítovec J, ©pinar J Diuretika u srdečního selhání. Kapit Kardiol 2002; 4: 90-92.
    125. Vítovec J, ©pinar J Který betablokátor u srdečního selhání? Studie COMET - dala jasnou odpověď? Cor Vasa 2003; 45: 527-528.
    126. Wang M, Yip GWK, Wang AYM et al. Independent and incremental prognostic value of early mitral annulus velocity in patients with impaired left ventricular systolic function. J Am Coll Cardiol 2005, 45: 272-277. Go to original source... Go to PubMed...
    127. Wang M, Yip GWK, Wang AYM et al. Peak early diastolic mitral annulus velocity by tissue doppler imaging adds independent and incremental prognostic value. J Am Coll Cardiol 2003; 41: 820-826. Go to original source... Go to PubMed...
    128. Widimský J Betablokátory v léčbě srdečního selhání. JAMA-CS 1999; 7: 375-377.
    129. Willenheimer R, van Veldhuisen DJ, Silke B et al. on behalf of the CIBIS III Investigators. Effect on Survival and Hospitalization of Initiating Treatment for Chronic Heart Failure With Bisoprolol Followed by Enalapril, as Compared With the Opposite Sequence Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005; 112: 2426-2435. Go to original source... Go to PubMed...
    130. Wilson Tang WH, Francis GS, Hoogwerf BJ et al. Fluid Retention After Initiation of Thiazolidinedione Therapy in Diabetic Patients With Established Chronic Heart Failure. JACC 2003; 41: 1394-1398. Go to original source... Go to PubMed...
    131. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. New Engl J Med 2000; 342: 145-153. Go to original source...
    132. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of kandesartan in patients with CHF and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777-781. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.